

Amaxa™ HT Nucleofector™ basic protocol for primary mammalian endothelial cells

Cell description

Large, flat adherent cells derived from mammalian endothelial cell tissues from various organs.

Note

Mammalian endothelial cells display significant phenotypic variations due to the wide range of both species and tissues from which they may be sourced.

This basic protocol describes how to easily define optimal Nucleofection™ conditions for different mammalian endothelial cells. We recommend to first test a set of pre-selected Nucleofector™ programs together with the P5 primary cell HT Nucleofector™ kit.

If you have questions regarding your endothelial cells of interest, please contact our scientific support team for further help with the optimization.

Product description

Recommended kits

P5 primary cell HT Nucleofector™ kits

Cat. No.	V5SP-5002
Size (reactions)	2×384
P5 primary cell HT Nucleofector™ solution	22.5 ml
Supplement	5 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	50 µg
384-well Nucleocuvette™ plate(s)	2

Cat. No.	V5SP-5010
Size (reactions)	10×384
P5 primary cell HT Nucleofector™ solution	90 ml
Supplement	20 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	150 µg
384-well Nucleocuvette™ plate(s)	10

Storage and stability

Store Nucleofector™ solution, supplement and pmaxGFP™ vector at 4°C. For long term storage, pmaxGFP™ vector is ideally stored at -20°C. The expiry date is printed on the solution box. Once the Nucleofector™ supplement is added to the Nucleofector™ solution it is stable for three months at 4°C.

Note

HT Nucleofector™ solutions can only be used with conductive polymer cuvettes, i.e. in the HT Nucleofector™, the well Shuttle™ device and in the 4D-Nucleofector™ system. They are not compatible with the Nucleofector™ II/2b device.

Optimization guidelines

The initial optimization experiment is comprised of 16 reactions: 7 different Nucleofector™ programs are tested in duplicate plus 1 control. The program, which turned out to be the most appropriate Nucleofection™ condition, should be used for all subsequent transfections.

The P5 primary cell HT Nucleofector™ solution has been tested successfully for the following cell types provided by Lonza:

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17–24
A	CA-167-AA	DY-138-AA	EH-100-AA	EP-114-AA	FA-100-AA	FF-138-AA	FP-100-AA	control	CA-167-AA	DY-138-AA	EH-100-AA	EP-114-AA	FA-100-AA	FF-138-AA	FP-100-AA	control	
B																	
C																	
D																	
E																	
F																	
G																	
H																	
I																	
J																	
K																	
L																	
M																	
N																	
O																	
P																	

Cell type	Lonza Cat. No.	Optimal program	Transfection efficiency	Viability*
HAEC (human aortic endothelial cells)	CC-2535	EH-100-AA	73 %	70 %
HMVEC-L (human lung microvascular endothelial cells)	CC-2527	FP-100-AA	79 %	48 %

*Determined by ViaLight™ Plus Kit, Lonza

Required material

Note

Please make sure that the entire supplement is added to the Nucleofector™ solution.

- HT Nucleofector™ system
- Supplemented HT Nucleofector™ solution at room temperature prior to Nucleofection™
- Supplied 384-well Nucleocuvette™ plates
- Supplied pmaxGFP™ Vector, stock solution 1 µg/µl

Note

Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2 µl for 20 µl reactions). For positive control using pmaxGFP™ vector, please dilute the stock solution to reach the appropriate working concentration.

- Substrate of interest, highly purified, preferably by using endotoxin free kits; A260 : A280 ratio should be at least 1.8
- 384-well Nucleocuvette™ plates are best handled with an automated liquid handling system. If manual pipetting is required please use compatible tips: epT.I.P.S. [US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266], Matrix TallTips™ [Matrix Technologies Corp., Cat. No. 7281] or LTS Tips [Rainin Instrument, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S]. Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ wells without getting stuck
- 384-well culture plates or culture plates of your choice
- For trypsinization: Please use trypsin as recommended by the cell supplier e.g. ReagentPack™ Subculture Reagent Kit containing Trypsin/EDTA, HEPES Buffered Saline Solution (HEPES-BSS) and Trypsin Neutralizing Solution (TNS) [Lonza; Cat. No. CC-5034]
- Culture medium: please use media as recommended by the cell supplier e.g. EGM™-2 BulletKit™ [Lonza; Cat. No. CC-3162] for HAEC [Lonza; Cat. No. CC-2535] and HUVEC [Lonza; Cat. No. CC-2517] or EGM™-2 MV BulletKit™ [Lonza; Cat. No. CC-3202] for HMVEC-L [Lonza; Cat. No. CC-2527]
- Pre-warm appropriate volume of culture medium to 37°C (122 µl per sample)
- Appropriate number of cells (5 × 10⁴–1 × 10⁵ cells per sample; lower or higher cell numbers may influence transfection results)

1. Pre Nucleofection™

Note

Transfection results may vary due to different culture conditions prior and post Nucleofection™. Especially endothelial cells show a dramatic decrease of transfection efficiency, if cells were grown confluent during subculture procedure (contact inhibition). Culture conditions may differ between cell types. Please follow your established procedure or the supplier's recommendations.

Cell Culture recommendations

- 1.1 Replace medium every 2–3 days
- 1.2 Cells should be passaged after reaching 70–80% confluency
- 1.3 Do not use cells after passage 9 for Nucleofection™ as this may lead to reduced viabilities and transfection efficiencies
- 1.4 Cells should be passaged 2–5 days before Nucleofection™ depending on growth rate of cells

Trypsinization

Note

Please follow your established procedure or the supplier's recommendations (e.g. for human aortic endothelial cells [Lonza; Cat. No. CC-2535] follow procedure described below).

- 1.5 Remove media from the cultured cells and wash cells once with HEPES-BSS
- 1.6 For harvesting, incubate the cells ~5 minutes at 37°C with recommended volume of indicated trypsinization reagent (please see required material)
- 1.7 Neutralize trypsinization reaction with TNS once the majority of the cells (>90%) have been detached

2. Nucleofection™

One Nucleofection™ sample contains

- 5 × 10⁴–1 × 10⁵ cells
 - 0.4 µg pmaxGFP™ vector or 0.4 µg plasmid DNA (in 1–2 µl H₂O or TE) or 30–300nM siRNA (0.6–6 pmol/sample)
 - 20 µl P5 primary cell HT Nucleofector™ solution
- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ solution
 - 2.2 Start HT Nucleofector™ software, verify device connection and upload experimental parameter file (for details refer to the HT Nucleofector™ manuals)

- 2.3 Select appropriate HT Nucleofector™ program. Please try all 7 Nucleofector™ programs (CA-167-AA, DY-138-AA, EH-100-AA, EP-114-AA, FA-100-AA, FF-138-AA and FP-100-AA) initially to determine the most appropriate Nucleofection™ condition for your specific endothelial cell type
- 2.4 Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media, e.g. 82 µl (see note at the end of this chapter) for one well of a 384-well plate and preincubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator
- 2.5 Pre-warm an aliquot of culture media to 37°C (40 µl per sample)
- 2.6 Prepare 0.4 µg pmaxGFP™ vector (recommended for initial optimization) or 0.4 µg plasmid DNA. For siRNA experiments we recommend to start using 30–300 nM siRNA (0.6–6 pmol/sample). Depending on cell type, the minimum effective siRNA concentration can range between 1 nM and 1 µM. To validate optimal conditions for down-regulation we recommend performing a time course (mRNA: 12–72 hours, protein/phenotype: 24–96 hours) in addition
- 2.7 Harvest the cells by trypsinization (please see 1.5–1.7)
- 2.8 Count an aliquot of the trypsinized cells and determine cell density
- 2.9 Centrifuge the required number of cells (5×10⁴–1×10⁵ cells per sample) at 90×g for 10 minutes at room temperature
- 2.10 Resuspend the cell pellet carefully in 20 µl room temperature HT Nucleofector™ solution per sample
- 2.11 Briefly shake the 384-well Nucleocuvette™ plate with an appropriate microtiter plate shaker to make sure the sample covers the bottom and sides of the wells without air bubbles. Alternatively thoroughly tap the 384-well Nucleocuvette™ plate
- 2.12 Place 384-well Nucleocuvette™ plate with closed lid onto the carousel of the plate handler of the HT Nucleofector™. Well “A1” must be in upper left position
- 2.13 Start Nucleofection™ process clicking “Start” in the HT Nucleofector™ software (for details refer to the HT Nucleofector™ manuals)
- 2.14 After run completion, carefully remove the 384-well Nucleocuvette™ plate from the carousel
- 2.15 Resuspend cells with desired volume of pre-warmed culture medium (maximum cuvette volume 60 µl). Mix cells by gently pipetting up and down two to three times. Recommendation for 96-well plates: Resuspend cells in 40 µl of pre-warmed media*
- 2.16 Plate desired amount of cells in culture system of your choice. Recommendation for 96-well plates: Transfer 18 µl of resuspended cells to 82 µl pre-warmed media

* Note

The indicated cell numbers and volumes produce optimal Nucleofection™ results in most cases. However, you may wish to test an extended range of cell numbers depending on your specific needs. Cell numbers and volumes can be adapted such that fewer cells are transferred or duplicate plates can be seeded.

A: One or several substrates (DNAs or RNAs) in multiples

- Prepare mastermixes by dividing cell suspension according to number of substrates
- Add required amount of substrates to each aliquot (max. 2 µl per sample)
- Transfer 20 µl of mastermixes into the wells of the 384-well Nucleocuvette™ plates

B: Multiple substrates (e.g. library transfection)

- Pipette 20 µl of cell suspension into each well of a sterile U-bottom 384-well microtiter plate
- Add 2 µl substrates (maximum) to each well
- Transfer 20 µl of cells with substrates into the wells of the 384-well Nucleocuvette™ plates

Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 384-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a liquid handling system or at least a multi-channel pipette with suitable pipette tips. As leaving cells in HT Nucleofector™ solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

3. Post Nucleofection™

- 3.1 Incubate the cells in a humidified 37°C/5% CO₂ incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4–8 hours. To validate optimal conditions for down regulation we recommend performing a time course (please see 2.6)

Additional information

Up-to-date list of all Nucleofector™ references

www.lonza.com/nucleofection-citations

Technical assistance and scientific support

USA/Canada

Tel 800 521 0390 (toll-free)

Fax 301 845 8338

scientific.support@lonza.com

Europe and Rest of World

Tel + 49 221 99199 400

Fax + 49 221 99199 499

scientific.support.eu@lonza.com

www.lonza.com

Lonza Cologne GmbH – 50829 Cologne, Germany

Please note that the Amaxa™ Nucleofector™ technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector™ technology, comprising Nucleofection™ process, Nucleofector™ device, Nucleofector™ solutions, Nucleofector™ 96-well Shuttle™ system, 96-well Nucleocuvette™ plates and modules, HT Nucleofector™ and 384-well Nucleocuvette™ plates is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH. TallTips are a registered trademark of Matrix Technologies Corporation.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtaining of such license. No statement is intended or should be construed as a recommendation to infringe an existing patent.

The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling.